secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001576885-24-000061
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen reports Q1 net loss of $14.9M; Phase 2 sabirnetug trial initiated
------------------------------------------------------------------------

- Net loss of $14.9M for Q1 2024 vs. $11.3M in Q1 2023; R&D expenses rose to $12.4M.
- Cash, equivalents and marketable securities totaled $296.6M as of March 31, 2024; expected to fund operations into H1 2027.
- First patient dosed in ALTITUDE-AD Phase 2 study of sabirnetug for early Alzheimer's in May 2024.
- Phase 1 subcutaneous dosing study of sabirnetug expected to start mid-2024; Lonza collaboration for manufacturing announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000157688524000061/0001576885-24-000061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000157688524000061/abos-20240514.htm
  HTML page:      https://secwatch.observer/filing/0001576885-24-000061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer